Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$14.53
-$0.11(-0.75%)
At close: 4:00 PM EDT
$14.53
-$0.11(-0.75%)
Day’s Range― - ―
52-Week Range$5.78 - $19.40
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.36M
Market Cap
$363.39M
Enterprise Value$622.17
Total Cash (Recent Filing)$117.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 18, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding26,525,160
10 Day Avg. Volume1,158,957
30 Day Avg. Volume1,364,040
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.67Price Target Upside159.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageEffectively zero debt and a materially larger equity base reduce refinancing and interest-cost risk for a development-stage biotech. This durable capital structure gives Tenax more optionality to fund clinical activities and negotiate partner terms over the next several quarters.
Long-term Supply And License StabilityA primary manufacturing supply deal plus an extended U.S. approval deadline materially lowers execution and timeline risk for commercialization. Defined forecasting, quality and cost-sharing terms support reliable scale-up and reduce a common bottleneck for launch-readiness.
Well-powered Phase 3 Program With High-profile SlotA large, statistically robust registrational trial and a late-breaking presentation at a major cardiology congress signal scientific validation and a clearer regulatory pathway. This strengthens the company's development program as a lasting strategic asset.
Bears Say
Pre-revenue OperationsNo product revenue means all operating spend must be financed externally until approval and launch. This persistent pre-revenue status is a structural constraint on self-funding, increasing reliance on capital markets or partners over the medium term.
Accelerating Cash Burn And Negative Cash FlowSubstantially larger negative free cash flow and consistently negative operating cashflows shrink runway and raise the likelihood of future financing. This persistent burn forces trade-offs on program funding and heightens dilution or refinancing risk over coming quarters.
Concentration Risk On Single Pivotal ProgramBusiness prospects are materially tied to one registrational trial outcome. That binary dependency is a lasting strategic vulnerability: an unfavorable result could stall approval, delay revenue generation, and significantly impair the company’s growth trajectory.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $5.78 and its highest was $19.40 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $363.39M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 104 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Jul 31, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.381 by $0.031.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 26,525,160 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.381. Following the earnings report the stock price went down -9.272%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (159.23% Upside)
$37.67 (159.23% Upside)
Blogger Sentiment
Bullish
TENX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.92%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$37.67
▲(159.23% Upside)
Technical Analysis
Enanta Pharmaceuticals
―
Arcturus Therapeutics
―
ProQR
―
Corbus Pharmaceuticals
―
Atea Pharmaceuticals
―
Ownership Overview
0.16% Insiders
12.05% Mutual Funds
0.43% Other Institutional Investors
77.07% Public Companies and
Individual Investors